发明名称 Treatment of coagulation disease by administration of recombinant VWF
摘要 The present invention provides methods of treating coagulation disease, including hemophilia and von Willebrand disease by administering recombinant von Willebrand Factor alone or in combination with Factor VIII.
申请公布号 US9272021(B2) 申请公布日期 2016.03.01
申请号 US201213493926 申请日期 2012.06.11
申请人 Baxalta Incorporated;Baxalta GmbH 发明人 Scheiflinger Friedrich;Turecek Peter;Ewenstein Bruce;Wong Wing Yen;Suiter Tobias M.
分类号 A61K38/36;A61P7/02;A61K38/37 主分类号 A61K38/36
代理机构 Morgan Lewis & Bockius LLP 代理人 Morgan Lewis & Bockius LLP
主权项 1. A method for treating Von Willebrand Disease or Hemophilia A in a subject in need thereof, the method comprising: intravenously administering to the subject a composition comprising recombinant Von Willebrand Factor (rVWF) wherein endogenous Factor VIII half-life is extended as compared to a subject administered plasma derived Von Willebrand Factor, wherein the rVWF is not modified with a water soluble polymer, wherein the composition is a high molecular weight VWF multimer composition comprising at least 20% VWF decamers or higher order multimers, and wherein the rVWF has a higher specific activity than plasma derived Von Willebrand Factor, and the higher order rVWF multimers are stable for at least 3 hours post-administration.
地址 Bannockburn IL US